Background--Thymosin beta-4 (TB4) is an X-linked gene product with cardioprotective properties. Little is known about plasma concentration of TB4 in heart failure (HF), and its relationship with other cardiovascular biomarkers. We sought to evaluate circulating TB4 in HF patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction compared to non-HF controls.
S ex differences in the epidemiology and pathophysiology of heart failure (HF) are well known. 1, 2 Women generally experience symptoms later in life, are less likely than men to present with ischemic disease, and predominate in the subset of HF with preserved ejection fraction (HFpEF). 3 However, unlike HF with reduced ejection fraction (HFrEF), clinical diagnosis of HFpEF remains challenging and controversial. 4 Established biomarkers such as N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hsTnT) are not specific for HFpEF. 5, 6 The need for insight into
HFpEF physiology is particularly acute as there are no therapeutic strategies proven to alter disease progression. 6 Mature thymosin beta-4 (TB4) is a highly conserved 43-amino acid peptide. 7, 8 When endogenous levels of TB4 are supplemented with exogenous delivery, animal models of cardiac injury show dramatic reduction in fibrosis, 9,10 increase in recruited stem cells, 11, 12 and preservation of EF. 10, 13 The underlying mechanism of TB4 cardioprotection has been attributed to increase in stem cell mobilization 11, 12 and angiogenesis as well as reduction in inflammation and apoptosis. 10, 14, 15 In cardiomyocyte culture, TB4 can prevent angiotensin II-induced hypertrophy, 16 activate integrin-linked kinase, 10 and upregulate copper/zinc superoxide dismutase and catalase to provide resistance to oxidative stress. 17 Clinical studies of circulating TB4 have been limited. A study of TB4 in HF patients undergoing cardiac stem cell infusion showed that TB4 was selectively elevated in patients who experienced symptomatic improvement. 18 Two other studies have correlated plasma TB4 level to the development of collateralization in patients with severe coronary artery disease. 19, 20 In this study, we quantified endogenous plasma levels of TB4 in 657 age-and sex-matched HF patients and controls, using liquid chromatography and mass spectrometry (LCMS). Although TB4 is an established cardioprotective molecule, little is known about the clinical significance of circulating TB4 in HF, including its source and regulation. To understand the broader soluble biomarker context of TB4 and provide hypothesis generation, we correlated TB4 measurements with a panel of 92 other cardiac biomarkers.
Methods

Patients and Study Design
The study cohort (n=657) was prospectively formed to comprise 219 non-HF controls, 219 HFpEF cases, and 219 patients with HFrEF selected for demographic comparability (ie, ethnicity, sex, and age). Patients with HF were chosen from the Singapore Heart Failure Outcomes and Phenotypes cohort 21 and control participants from the Singapore Longitudinal Aging Study. 22 Singapore Heart Failure Outcomes patients were either those admitted with primary diagnosis of acute decompensated HF according to European Society of Cardiology criteria, 23 or those attending an outpatient clinic for management of HF with a history of an acute decompensated HF admission within the previous 6 months. Patients with HF attributable to infiltrative or congenital heart disease were excluded. Non-HF control participants subselected from the Singapore Longitudinal Aging Study cohort were free of coronary artery disease or HF by history and clinical and echocardiographic examination. Both Singapore Heart Failure Outcomes and Singapore Longitudinal Aging Study studies were approved by the ethics review board of each participating institution and complied with the Declaration of Helsinki. Informed and signed consent was provided by all participants in this study. Importantly, blood sampling and other assessments were all undertaken with patients in the stable compensated state (ie, shortly before discharge or during outpatient consultation). Blood samples were taken into EDTA tubes with prompt separation by centrifuging at 1485 g with cooling, and the plasma stored at À80°C pending assay.
Measurement of Biomarkers
Measurement of plasma NT-proBNP and hsTnT has been previously described. 24 NT-proBNP and hsTnT concentrations were determined by electro-chemiluminescence immunoassay using the NT-proBNP II and troponin T high-sensitivity assays, respectively, on an ELECSYS Cobas e411 immunoanalyzer (Roche Diagnostics GmbH, Mannheim, Germany). The ranges of measurement for NT-proBNP and hsTnT assays were 5 to 35 000 pg/mL and 3 to 10 000 pg/mL, respectively. Mean concentrations and interassay coefficient of variation of samples used for quality control, presented as mean (coefficient of variation), were established in-house. Low-concentration NT-proBNP and hsTnT quality control samples averaged at 141 pg/mL (3.38%) and 26.7 pg/mL (6.66%), respectively; high NT-proBNP and hsTnT samples averaged at 4759 pg/mL (4.03%) and 2090 pg/mL (4.06%), respectively. A multiplex biomarker panel based on proximity extension technology was also utilized to get relative quantification on a panel of 92 biomarkers (Proseek Multiplex CVD I, Olink Proteomics AB, Uppsala, Sweden). Figure S1 ). For quality control, rabbit plasma spiked with 1700, 700, and 100 ng/mL of TB4 were also run in each LCMS/MS batch. The mean (coefficient of variation) measured for each quality control were 1809 ng/mL (5.0%), 660 ng/mL (3.7%), and 116 ng/mL (2.3%), respectively. Where TB4 levels exceeded the quantification range, plasma sample was diluted using rabbit plasma before requantification.
Sample Preparation for LCMS/MS
Human plasma samples (50 lL) were aliquoted into a 96-well plate, then spiked with 100 lL of 1 lg/mL TB4 heavy isotope standard. After treating with 150 lL of acetonitrile, the plate was mixed on a shaker at 1000 rpm/min for 5 minutes, then spun down at 4000g for 20 minutes at 4°C. Fifty microliters of the supernatant was carefully transferred to a 96-microwell plate and further diluted with 50 lL of ultrapure water containing 0.2% formic acid. The 96-microwell plate containing the diluted filtrate was then loaded into the auto-sampler for analysis by LCMS/MS. Ion counts were then normalized against that of the heavy isotope standard, before using the standard curve for quantification. Values are mean (AESD), median (interquartile range), or n (%). ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimate glomerular filtration rate; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hsTnT, high sensitivity troponin T; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association (functional class); OR, odds ratio; TB4, thymosin beta-4.
Statistical Analyses
from the initial univariate analysis are then entered into a multivariate linear regression model to be estimated by the least-squares method. A final model is then derived by using backward elimination with a cutoff P-value of 0.05. The ability of TB4 and NT-proBNP to discriminate HF (and its subgroups HFpEF and HFrEF) from control was evaluated by receiver operating curve analysis. Assessment of the prognostic performance (for time to 2-year all-cause mortality) of TB4 was conducted by comparing Kaplan-Meier survival functions using log-rank test, and generalized structure equation modeling (gSEM), a modelbuilding framework that allows for complex data interaction to be accommodated with ease. 25, 26 Weibull distribution with log link were used to handle time to all-cause mortality, and "robust" standard errors correction was applied in anticipation of potential bias caused by some outliers. Pairwise correlation of Ln TB4, Ln NTproBNP, Ln hsTnT, and the panel of 92 biomarkers was done using the "matpwcorr" module on STATA with Bonferroni correction. Significant correlates of Ln TB4 were then ranked by Pearson correlation coefficient. Graphical representation of the correlation was generated using the "corrplot" package in RStudio (Version 0.99.902) with "hclust" ordering.
Results
Cohort Characteristics
Cohort characteristics are shown in Table 1 . In agreement with previous reports, in our cohort, hypertension was more common in HFpEF, 4 ischemic etiology more common in HFrEF, and NT-proBNP levels were highest in HFrEF. 27 Median level (interquartile values) of plasma TB4 was 985 (421-1723) ng/mL in controls, 1401 (720-2379) ng/mL in HFpEF, and 1106 (556-1955) ng/mL in HFrEF. 
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P-values were corrected with Bonferroni correction. HF indicates heart failure; HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IQR, interquartile range; TB4, thymosin beta-4. *Bonferroni correction for 16 comparisons.
Pairwise Comparison of TB4 Levels by Sex and HF Status
We performed pairwise comparison of TB4 levels by HF status and sex ( These stratified data are further presented as a boxplot in Figure 1 . The distributions of TB4 within male and female HF populations were similar with an interquartile range for male patients with HF of 1345 ng/mL versus 1405 ng/mL for female patients with HF.
Clinical Correlates of TB4
To identify clinical correlates of plasma TB4 in the HF cohort, we examined 33 clinical variables including those previously identified to associate with mortality in HF, using a univariate linear regression (Table S1 ). Statistically significant variates were then included in a multivariate model for refinement by backward elimination. The 6 significant correlates of TB4 included in the final multivariate model (Table 3) were the following: sex (TB4 is elevated in women), peripheral vascular disease (elevated), diastolic blood pressure (inversely related), New York Heart Association (NYHA) class (elevated in higher classes), hsTnT levels (positively correlated), and left ventricular ejection fraction (positively correlated). Notably, Ln TB4 did not significantly correlate with Ln NT-proBNP. Established biomarkers NT-proBNP and hsTnT were also subjected to the same multivariate analysis (Tables S2 and S3 ) but only TB4 was significantly higher in women. As expected, hsTnT was significantly higher in men.
Biomarker Correlates of TB4
As TB4 levels seemed to be sex specific and were independent of NT-proBNP, we attempted to discover other possible biomarkers indicative of candidate pathophysiological pathways that may correlate with TB4. TB4 correlated best with CD40 ligand/CD154 (R=0.755, P<0.001), pro-epidermal growth factor (R=0.744, P<0.001), heat shock 27-kDa protein -HSP27 (R=0.739, P<0.001), NF-kappa-B essential modulator (R=0.733, P<0.001), proto-oncogene tyrosine-protein kinase Src (R=0.730, P<0.001), integrin beta 1 binding protein 2 (melusin) (R=0.712, P<0.001), and Nicotinamide adenine dinucleotide-dependent deacetylase sirtuin-2 (R=0.708, P<0.001) (Figure 2) . A full list of the 92 biomarkers and their correlation coefficient with TB4 are provided in Table S4 . A visualization of the correlation matrix ordered with hierarchal clustering is shown in Figure S2 , and the scatter plot of the wellcorrelated biomarkers is shown in Figure 2 .
Diagnostic Performance of TB4
As TB4 was significantly elevated in female patients with HFpEF, we hypothesized that TB4 may have diagnostic utility for HFpEF in women. We evaluated the performance of TB4 in discriminating between HFpEF and control women by receiver operating curve analysis, which yielded an area under curve of 0.679 (95% CI: 0.609-0.748; P<0.001). The corresponding area under curve for NT-proBNP was 0.908 (0.867-0.949). Consistent with TB4 being significantly elevated selectively in women, the areas under curve were nondiscriminatory in male patients ( Figure 3 ).
Kaplan-Meier Curves for All-Cause Mortality
Over 2 years' follow-up among patients with HF, there were a total of 60 deaths (33 in men, 27 in women). To investigate whether TB4 has prognostic value, we grouped HF patients by their TB4 levels into the top tertile and lower 2 tertiles. Kaplan-Meier survival curves were constructed for 2-year all-cause mortality ( Figure 4) . When all HF patients were considered (cutoff value=1769 ng/mL, P=0.1638), or analysis was confined to men (cutoff value=1452 ng/mL, P=0.9910), the difference in survival functions between the top and bottom 2 tertiles was not statistically significant. In contrast, for female patients with HF, the difference in survival functions was significant (cutoff value=2000 ng/mL, P=0.0128). Synergism between NT-proBNP and TB4 was assessed by splitting patients into 4 groups based on whether they were above or below Figure 3 . ROC values of TB4 for selected HF (heart failure) diagnosis scenarios. Error bar denotes 95% CI. TB4 only has significant diagnostic value in scenarios with women. Both sexes ( ), men only ( ), and women only ( ). AUC indicates area under curve; HFpEF patients with heart failure with preserved ejection fraction; HFrEF, patients with heart failure with reduced ejection fraction; ROC, receiver operating curve; TB4, thymosin beta-4.
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median levels of NTproBNP and TB4. TB4 further split the risk group (P=0.027) in patients with below median levels of NT-proBNP ( Figure S3 ). There were too few deaths in the subgroup of HFpEF (n=24) and HFrEF (n=36) to allow for further stratified analysis by HF type.
gSEM Modeling of TB4 and Clinical Outcomes
To evaluate whether TB4 has prognostic value independent of NT-proBNP in HF, we used gSEM to model TB4's contribution to all-cause mortality. The use of gSEM over conventional Cox regression modeling allowed us to account for potential interactions between variables. In the full model, NT-proBNP, age, NYHA class, and history of myocardial infarction were significant (Table 4) . In determining the number of variables to retain, we followed the rule of 5 to 9 events per variable. 28 In our refined model (Table 5) , we retained 4 variables: NTproBNP, age, NYHA class, and history of myocardial infarction, eGFR indicates estimated glomerular filtration rate; gSEM, generalized structured equation modeling; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association (functional class); TB4, thymosin beta-4. *Statistically significant which was significant in the full model (Table 4) , and added TB4. In men, only age and NYHA class remained significant while in women, TB4 was independently predictive of 2-year all-cause mortality, alongside NYHA class and history of myocardial infarction. Likewise, we note the same trends were observed (including statistical significance of TB4) using the above inputs to a standard Cox regression model.
Discussion
Sex differences in HF are consistently seen in cohort studies. 1, 2, 29 Both the Framingham heart study 30 and the Rotterdam study 31 reveal that while lifetime risk of HF is similar in both sexes, clinical onset is earlier in men than women. Women also have a survival advantage over men upon diagnosis. [32] [33] [34] [35] Ischemic heart disease dominates in men, while systolic hypertension dominates in women. 36 Potentially reflective of these risk factors, female patients are twice as likely as men to develop HFpEF. 3 We studied endogenous plasma TB4 and found its level to be significantly elevated in HF. In a segmented analysis, we found that it was female HFpEF that accounted for the observed differences, although diagnostic performance of TB4 is still modest compared to NT-proBNP and hsTnT even in this subgroup. TB4 was a significant prognostic marker for 2-year mortality in female patients with HF via Kaplan-Meier analysis and gSEM modeling. We observed that inclusion of both NTproBNP and hsTnT left a large proportion of gSEM variables insignificant. We thus chose NT-proBNP as the more stringent HF biomarker and omitted hsTnT from gSEM modeling. The relationship between TB4 and hsTnT may therefore benefit from additional study.
To gain insight into the functional context of TB4, we used a hierarchical clustering algorithm to define cross-correlative networks of soluble biomarkers in the 92-member multiplex panel. Applying a cutoff value of Pearson correlation coefficient (R) >0.7 and P-value <10 À10 , we find that TB4 lies tightly within a cluster of 7 biomarkers, 6 of which are either X-linked or involved in sex hormone signaling. Thus, while we emphasize the need for replication studies, the nature of this correlative cluster is consistent with a sex differential role for TB4 in our studied cohort. The top correlate was soluble plasma CD40 ligand, an Xlinked immune mediator involved in inflammatory and vascular diseases, 37 which is regulated by NF-jB 38 and a marker of cardiac events in healthy women. 39 Soluble plasma CD40
ligand is elevated in diseases with strong female prevalence: Hashimoto thyroiditis (95% female), 40 systemic lupus erythematosus (88% female), 41 and Sj€ ogren syndrome (92% female). 41 ITGB1BP2 (melusin) is also an X-linked gene and a known protective factor in cardiac injury. 42 Another correlate, NF-kappa-B essential modulator, is an X-linked gene that is cardioprotective in experimental HF through NF-jB-mediated modulation of oxidative stress. 43 HSP27 is also cardioprotective and activates the NF-jB pathway 44, 45 ; its secretion is regulated by estrogen 46 and shows elevated expression levels in HFpEF. 47 Epidermal growth factor and Src are both part of the extranuclear estrogen signaling network, 48 can also activate the NF-jB pathway, 49 and play a role in both vascular and immune processes. 50 The seventh member of the cluster, sirtuin-2, regulates NF-jB-dependent gene expression. 51 Thus, within our analysis, TB4 is associated with markers of sex-specific biology as well as the NF-jB pathway, a central pathway in immune system activation, tolerance, and autoimmune pathophysiology.
52 TB4 has been shown to inhibit the NF- jB pathway in a mouse model of myocardial infarction 53 and in tumor necrosis factor a-stimulated corneal epithelial cells. 54 We also note that inhibition of NF-jB resulted in suppression of TB4 expression in a prior study of melanoma cells. 55 A mechanism for the higher levels of TB4 in females is suggested by the chromosomal location of the TB4 gene (TMSB4X). TMSB4X is located on the third evolutionary stratum of the X-chromosome (Xp22.2), a region highly predicted to XCi escape. The genes flanking TMSB4X on either side, TLR7/8 and FAM9C, each has empirical evidence for XCi escape. 56, 57 We thus hypothesize that increased transcriptional dosing via XCi escape may contribute to sex differences in TB4. Our current study is limited by cohort size, as the observed TB4 elevation is confined primarily to the female HFpEF subgroup. Likewise, the relatively small sample size, 106 male controls versus 221 male HF, may contribute to the statistical nonsignificance in males; thus, replication studies in additional cohorts will be required to fully establish TB4 sex specificity. Clinical outcomes were also limited because of sample and subsample sizes and a relatively short observation period of 2 years. However, given the body of evidence supporting TB4 as cardioprotective factor, our observations of TB4 levels in women with HF and multiple associations with sex-related biology, we hypothesize TB4 as a component of the immunopathophysiology of HF, potentially accentuated in women through increased transcriptional dosing and Xi escape. Next steps will include in vitro studies and prospective validation in both acute and compensated HF and acute cardiac injury.
Conclusions
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